ImmunoGuard

ImmunoGuard is a Swiss clinical-stage biopharmaceutical company focused on developing treatments for Systemic Inflammatory Response Syndrome (SIRS). A spin-off from the University of Bern and the University Hospital Bern, the company addresses the severe inflammatory complications that can occur after major surgeries, particularly cardiac surgery involving heart-lung machines. Their lead program utilizes a C1-esterase inhibitor to modulate the innate immune system and prevent multi-organ dysfunction. By targeting the underlying causes of hyper-inflammation, ImmunoGuard seeks to improve patient recovery and reduce the burden on intensive care units. The company is backed by prominent Swiss venture capital firms and is currently advancing its lead candidate through clinical development.